FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3013281025> ?p ?o ?g. }

• W3013281025 endingPage "45" @default.
• W3013281025 startingPage "39" @default.
• W3013281025 abstract "Background Chronic nodular prurigo (CNPG) is a multifactorial skin disease characterized by itchy papules and nodules, usually resistant to standard treatment and associated with markedly impaired quality of life. Objective To describe dupilumab effectiveness and tolerability in treating adult patients with CNPG refractory to both topical and systemic therapies. Methods Retrospective, multicenter study including adult patients affected by CNPG, who were treated with dupilumab for at least 16 weeks. Results Twenty-seven CNPG patients showed clinical improvement in terms of skin lesions, itch, sleeplessness, and quality of life. A consistent proportion of patients (24/27; 88.9%) had at least 16-week continuous treatment and achieved Investigator Global Assessment score 1 (11/24; 45.8%). An increased number of patients achieved at least a 2-grade reduction in Investigator Global Assessment score (19/24; 79.2%). Numeric rating scale values for itch and sleeplessness decreased from 8.9 to 2.7 and from 8.2 to 1.7, respectively (P < .001) after 16-week therapy. Ten patients achieved 36 weeks of continuous treatment while maintaining clinical efficacy. Limitations Major limitations included lack of validated assessment tools at the initial data collection, a limited cohort of treated patients, and a short-term observation period. Conclusion Dupilumab was proven effective in reducing itch and improving CNPG skin lesions. Chronic nodular prurigo (CNPG) is a multifactorial skin disease characterized by itchy papules and nodules, usually resistant to standard treatment and associated with markedly impaired quality of life. To describe dupilumab effectiveness and tolerability in treating adult patients with CNPG refractory to both topical and systemic therapies. Retrospective, multicenter study including adult patients affected by CNPG, who were treated with dupilumab for at least 16 weeks. Twenty-seven CNPG patients showed clinical improvement in terms of skin lesions, itch, sleeplessness, and quality of life. A consistent proportion of patients (24/27; 88.9%) had at least 16-week continuous treatment and achieved Investigator Global Assessment score 1 (11/24; 45.8%). An increased number of patients achieved at least a 2-grade reduction in Investigator Global Assessment score (19/24; 79.2%). Numeric rating scale values for itch and sleeplessness decreased from 8.9 to 2.7 and from 8.2 to 1.7, respectively (P < .001) after 16-week therapy. Ten patients achieved 36 weeks of continuous treatment while maintaining clinical efficacy. Major limitations included lack of validated assessment tools at the initial data collection, a limited cohort of treated patients, and a short-term observation period. Dupilumab was proven effective in reducing itch and improving CNPG skin lesions." @default.
• W3013281025 created "2020-04-03" @default.
• W3013281025 creator A5003743100 @default.
• W3013281025 creator A5015050981 @default.
• W3013281025 creator A5016818733 @default.
• W3013281025 creator A5017062027 @default.
• W3013281025 creator A5019637171 @default.
• W3013281025 creator A5072653864 @default.
• W3013281025 creator A5074398260 @default.
• W3013281025 creator A5077261955 @default.
• W3013281025 date "2020-07-01" @default.
• W3013281025 modified "2023-10-11" @default.
• W3013281025 title "Dupilumab improves clinical manifestations, symptoms, and quality of life in adult patients with chronic nodular prurigo" @default.
• W3013281025 cites W1491767948 @default.
• W3013281025 cites W1504410502 @default.
• W3013281025 cites W1537248210 @default.
• W3013281025 cites W1554986750 @default.
• W3013281025 cites W1589746310 @default.
• W3013281025 cites W2013931408 @default.
• W3013281025 cites W2043956972 @default.
• W3013281025 cites W2077529892 @default.
• W3013281025 cites W2086182737 @default.
• W3013281025 cites W2524051065 @default.
• W3013281025 cites W2570968593 @default.
• W3013281025 cites W2610814011 @default.
• W3013281025 cites W2752706812 @default.
• W3013281025 cites W2753646323 @default.
• W3013281025 cites W2770157388 @default.
• W3013281025 cites W2771011851 @default.
• W3013281025 cites W2801642492 @default.
• W3013281025 cites W2891396683 @default.
• W3013281025 cites W2901974522 @default.
• W3013281025 cites W2924758607 @default.
• W3013281025 cites W2944694531 @default.
• W3013281025 cites W2952790398 @default.
• W3013281025 cites W2953922585 @default.
• W3013281025 cites W2959876937 @default.
• W3013281025 cites W2969363587 @default.
• W3013281025 cites W2972531102 @default.
• W3013281025 cites W2973441550 @default.
• W3013281025 cites W4237210808 @default.
• W3013281025 doi "https://doi.org/10.1016/j.jaad.2020.03.049" @default.
• W3013281025 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32229281" @default.
• W3013281025 hasPublicationYear "2020" @default.
• W3013281025 type Work @default.
• W3013281025 sameAs 3013281025 @default.
• W3013281025 citedByCount "40" @default.
• W3013281025 countsByYear W30132810252020 @default.
• W3013281025 countsByYear W30132810252021 @default.
• W3013281025 countsByYear W30132810252022 @default.
• W3013281025 countsByYear W30132810252023 @default.
• W3013281025 crossrefType "journal-article" @default.
• W3013281025 hasAuthorship W3013281025A5003743100 @default.
• W3013281025 hasAuthorship W3013281025A5015050981 @default.
• W3013281025 hasAuthorship W3013281025A5016818733 @default.
• W3013281025 hasAuthorship W3013281025A5017062027 @default.
• W3013281025 hasAuthorship W3013281025A5019637171 @default.
• W3013281025 hasAuthorship W3013281025A5072653864 @default.
• W3013281025 hasAuthorship W3013281025A5074398260 @default.
• W3013281025 hasAuthorship W3013281025A5077261955 @default.
• W3013281025 hasConcept C121332964 @default.
• W3013281025 hasConcept C126322002 @default.
• W3013281025 hasConcept C142424586 @default.
• W3013281025 hasConcept C159110408 @default.
• W3013281025 hasConcept C16005928 @default.
• W3013281025 hasConcept C167135981 @default.
• W3013281025 hasConcept C197934379 @default.
• W3013281025 hasConcept C205545832 @default.
• W3013281025 hasConcept C2776173921 @default.
• W3013281025 hasConcept C2776266956 @default.
• W3013281025 hasConcept C2778329239 @default.
• W3013281025 hasConcept C2778375690 @default.
• W3013281025 hasConcept C2779134260 @default.
• W3013281025 hasConcept C2779824493 @default.
• W3013281025 hasConcept C2779951463 @default.
• W3013281025 hasConcept C2781431837 @default.
• W3013281025 hasConcept C30036603 @default.
• W3013281025 hasConcept C71924100 @default.
• W3013281025 hasConcept C72563966 @default.
• W3013281025 hasConcept C87355193 @default.
• W3013281025 hasConceptScore W3013281025C121332964 @default.
• W3013281025 hasConceptScore W3013281025C126322002 @default.
• W3013281025 hasConceptScore W3013281025C142424586 @default.
• W3013281025 hasConceptScore W3013281025C159110408 @default.
• W3013281025 hasConceptScore W3013281025C16005928 @default.
• W3013281025 hasConceptScore W3013281025C167135981 @default.
• W3013281025 hasConceptScore W3013281025C197934379 @default.
• W3013281025 hasConceptScore W3013281025C205545832 @default.
• W3013281025 hasConceptScore W3013281025C2776173921 @default.
• W3013281025 hasConceptScore W3013281025C2776266956 @default.
• W3013281025 hasConceptScore W3013281025C2778329239 @default.
• W3013281025 hasConceptScore W3013281025C2778375690 @default.
• W3013281025 hasConceptScore W3013281025C2779134260 @default.
• W3013281025 hasConceptScore W3013281025C2779824493 @default.
• W3013281025 hasConceptScore W3013281025C2779951463 @default.
• W3013281025 hasConceptScore W3013281025C2781431837 @default.
• W3013281025 hasConceptScore W3013281025C30036603 @default.
• W3013281025 hasConceptScore W3013281025C71924100 @default.

• next